|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
7 November 2016 |
|
Main ID: |
NCT02606019 |
|
Date of registration:
|
09/11/2015 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
The Use of Biomarkers in Predicting Dengue Outcome
|
|
Scientific title:
|
The Use of Biomarkers in Predicting Dengue Outcome |
|
Date of first enrolment:
|
October 2015 |
|
Target sample size:
|
108 |
|
Recruitment status: |
Recruiting |
|
URL:
|
https://clinicaltrials.gov/show/NCT02606019 |
|
Study type:
|
Observational |
|
Study design:
|
Observational Model: Cohort, Time Perspective: Prospective
|
|
Phase:
|
N/A
|
|
|
Countries of recruitment
|
|
Malaysia
| | | | | | | |
|
Contacts
|
|
Name:
|
Gary Low, MPH |
|
Address:
|
|
|
Telephone:
|
+60123150115 |
|
Email:
|
garylowkk@utar.edu.my |
|
Affiliation:
|
|
|
|
Name:
|
Gary Low |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Universiti Tunku Abdul Rahman |
| |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Participants who are age 15 or more.
- Participants must be recruited within the first three days of fever.
- Positive dengue by NS1Ag. Confirmed later on by paired dengue IgM/IgG.
- Final diagnosis of severe dengue or non-severe dengue.
Exclusion Criteria:
- Participants who are less than 15 years old.
- Pregnant mothers.
- Participants should not have autoimmune disorder, haematological disorder, cancer,
cardiovascular disease, on long term warfarin and aspirin.
- Participants who have been previously treated with dengue infection (secondary dengue
infection will be excluded by dengue IgM/IgG).
Age minimum:
15 Years
Age maximum:
N/A
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Dengue
|
|
Primary Outcome(s)
|
|
Negative predictive value (%) of biomarkers (PTX3 and VEGF)
[Time Frame: upon study completion, 3 years]
|
|
Positive predictive value (%) of biomarkers (PTX3 and VEGF)
[Time Frame: upon study completion, 3 years]
|
|
Sensitivity (%) of biomarkers (PTX3 and VEGF)
[Time Frame: upon study completion, 3 years]
|
|
Specificity (%) of biomarkers (PTX3 and VEGF)
[Time Frame: upon study completion, 3 years]
|
|
Secondary Outcome(s)
|
|
Correlation of routine blood parameters with PTX 3 and VEGF.
[Time Frame: upon study completion, 3 years]
|
|
Secondary ID(s)
|
|
NMRR-15-1045-25937
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|